In the past decade, advanced lung cancer and melanoma have witnessed a surge in Food and Drug Administration (FDA)–approved treatment innovations. Yet, the impact of these advancements on ...

To advance the call to action to optimize dosage of anticancer agents, FDA and ASCO cosponsored two multistakeholder workshops, Getting the Dose Right: Optimizing Dose Selection Strategies in Oncology ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

APOLLO: Optimizing the Treatment of High-Risk Acute Promyelocytic Leukemia With All-Trans Retinoic Acid and Arsenic Trioxide While Minimizing the Role of Chemotherapy The following represents ...

In the article that accompanies this editorial, Dr Zhang et al 7 report on a randomized controlled trial in which patients with cT1N0 invasive adenocarcinoma with a consolidation-to-tumor ratio ≤0.5 ...

PURPOSEPancreatic cancer is one of the most lethal cancers in the United States. Many patients with pancreatic cancer ultimately require end-of-life (EOL) care, which encompasses various aspects, ...

Bladder cancer (BLCA) ranks as the tenth most common malignancy worldwide, with rising incidence and mortality rates. Owing to its molecular and clinical heterogeneity, BLCA is associated with high ...

It was a typical morning in the oncology outpatient clinic. The day was unfolding with its usual cadence. Charts were flipped, the air buzzed with protocol adjustments, and cycles were discussed with ...

PURPOSEWe conducted a phase II, multicenter trial (ClinicalTrials.gov identifier: NCT03427866) investigating ruxolitinib administration before, during, and after allogeneic hematopoietic cell ...

This study investigates the incidence and clinicopathologic characteristics of head and neck cancer (HNC) in the Surinamese population, with an emphasis on the burden of human papillomavirus (HPV) and ...

Human epidermal growth factor receptor 2 (HER2)–positive breast cancer (HER2+BC) is linked to poorer outcomes. Trastuzumab is the standard treatment, but its high cost limits access in ...

Many seriously ill patients receive much of their care at home from one or more family members. However, shared decision making (SDM)—the collaborative process whereby clinicians and patients work ...